Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Astellas Pharma Inc (ALPMY)

Astellas Pharma Inc (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astellas Pharma Inc 2-5-1 Nihonbashi-Honcho Chuo-Ku Tokyo M0 103-8411 JPN

www.astellas.com P: 813-3244-3000

Description:

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.

Key Statistics

Overview:

Market Capitalization, $K 17,173,702
Enterprise Value, $K 14,340,702
Shares Outstanding, K 1,809,663
Annual Sales, $ 11,418 M
Annual Net Income, $ 742,000 K
Last Quarter Sales, $ 2,857 M
Last Quarter Net Income, $ 126,320 K
EBIT, $ 400,500 K
EBITDA, $ 2,084 M
60-Month Beta 0.32
% of Institutional Shareholders 0.00%
Float, K 1,809,663
% Float 100.00%
Short Volume Ratio 0.29

Growth:

1-Year Return -37.04%
3-Year Return -36.71%
5-Year Return -28.81%
5-Year Revenue Growth -6.92%
5-Year Earnings Growth 21.33%
5-Year Dividend Growth 34.78%

Per-Share Information:

Most Recent Earnings 0.12 on 02/05/24
Latest Earnings Date 04/25/24 [--]
Earnings Per Share ttm 0.39
EPS Growth vs. Prev Qtr 1,300.00%
EPS Growth vs. Prev Year -55.56%
Annual Dividend Rate, $ 0.17
Annual Dividend Yield 1.77%
Most Recent Dividend 0.168 on 09/27/23
Next Ex-Dividends Date 09/27/23
Dividend Payable Date 12/18/14
Dividend Payout Ratio 81.89%
Most Recent Split 5-4 on 04/02/14

ALPMY Ratios

Ratio
Price/Earnings ttm 24.44
Price/Earnings forward 19.19
Price/Earnings to Growth 1.37
Return-on-Equity % 6.39%
Return-on-Assets % 3.29%
Profit Margin % 6.50%
Debt/Equity 0.58
Price/Sales 1.56
Price/Cash Flow 7.00
Price/Book 1.68
Book Value/Share 5.65
Interest Coverage 16.08

ALPMY Dividends

Date Value
09/27/23 $0.1680
03/29/23 $0.1530
09/29/22 $0.1560
03/28/22 $0.1370
09/27/21 $0.1560
03/29/21 $0.1360
09/25/20 $0.1430
03/26/20 $0.1360
09/25/19 $0.1570
09/26/18 $0.1670
03/29/18 $0.1170
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar